Search results
Author(s):
William E Boden
,
Juan Carlos Kaski
,
C Noel Bairey Merz
,
et al
Added:
10 months ago
Author(s):
William Gray
Added:
10 months ago
Safety and effectiveness outcomes of a 3-in-1 carotid stent delivery system show no major strokes at 30-day and one-year follow ups and significantly low rates of clinically driven target lesion revascularisation at two years.Dr William Gray (Main Line Health, Pennsylvania, US) joins us to discuss the first European presentation of the two-year outcomes from PERFORMANCE II (NCT04201132; Contego…
View more
Author(s):
Mohammed Sallam
,
Hossameldin Hassan
,
Derek Connolly
,
et al
Added:
1 year ago
Link Between NAFLD/NASH and Cardiometabolic Syndrome
Author(s):
Sheila Gato
,
Vanessa García-Fernández
,
Antonio Gil-Gómez
,
et al
Added:
1 year ago
Review Article
Updates on Chronic Coronary Syndrome
Author(s):
Filippo Gurgoglione
,
Giampaolo Niccoli
Added:
1 year ago
Editorial
ESC 25: The CARUSO Trial
Author(s):
Tiziana Claudia Aranzulla
Added:
6 months ago
Video
Author(s):
Samineh Sehatbakhsh
Added:
6 months ago
Navigate the complex landscape of coronary interventions following transcatheter aortic valve replacement with Dr Samineh Sehatbakhsh, addressing critical access challenges in an era of expanding TAVR indications.This essential presentation, part of the Complex Cases track, examines the growing clinical significance of post-TAVR coronary access as procedures expand to younger, lower-risk patients…
View more
TCT 23: PICSO-AMI-I
Author(s):
Giovanni Luigi Di Maria
Added:
2 years ago
Video
Author(s):
Rasha Al-Lamee
,
Michael Foley
Added:
1 year ago
ACC.24 — Investigators, Dr Rasha K Al-Lamee and Dr Michael Foley (Imperial College London, UK) joined us to discuss the ORBITA COSMIC trial (NCT04892537).This randomized, double-blinded, placebo-controlled trial investigated the effects of coronary sinus reducer (CSR) as compared to placebo on myocardial perfusion via MRI, exercise duration, and symptoms in patients with refractory angina and…
View more
Author(s):
Mads Brix Kronborg
Added:
2 years ago
ESC 2023 — Dr Mads Brix Kronborg (Aarhus University Hospital, DE) joins us to discuss the findings from the DANPACE II Trial (NCT00236158).
DANPACE II (The DANPACE Investigator Group) trial aimed to compare patients who were randomised in a 1:1 ratio to either a base rate of 60 beats per minute and rate-adaptive DDD (DDDR-60 Group) or a base rate of 40bpm and non-rate adaptive DDD (DDD-40…
View more